CART%20Cell%20Therapy
Showing 26 - 50 of >10,000
Relapsed Neuroblastoma, Refractory Neuroblastoma, Relapsed Osteosarcoma Trial in Houston (C7R-GD2.CART cells, Cyclophosphamide,
Recruiting
- Relapsed Neuroblastoma
- +6 more
- C7R-GD2.CART cells
- +2 more
-
Houston, Texas
- +1 more
Nov 12, 2021
B-All, Acute Lymphoblastic Leukemia Trial run by the National Cancer Institute (NCI) (NGS testing)
Not yet recruiting
- B-All
- Acute Lymphoblastic Leukemia
- NGS testing
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Feb 2, 2023
Leukemia, Lymphoma Trial in Beijing (Anti-CD22-CAR-transduced T cells)
Unknown status
- Leukemia
- Lymphoma
- Anti-CD22-CAR-transduced T cells
-
Beijing, Beijing, ChinaFengtai District
Feb 6, 2021
Solid Tumor Trial (HER2-E-CART cells)
Not yet recruiting
- Solid Tumor
- HER2-E-CART cells
- (no location specified)
Feb 16, 2023
Acute Myeloid Leukemia (AML), Multiple Myeloma (MM) Trial (3x10(6) CART-38 cellls, 7x10(5) CART-38 cells, 7x10(6) CART-38 cells)
Not yet recruiting
- Acute Myeloid Leukemia (AML)
- Multiple Myeloma (MM)
- 3x10(6) CART-38 cellls
- +5 more
- (no location specified)
Jul 15, 2022
Diffuse Intrinsic Pontine Glioma, High Grade Glioma, Embryonal Tumor Trial in Houston ((C7R)-GD2.CART cells, Cyclophosphamide,
Recruiting
- Diffuse Intrinsic Pontine Glioma
- +3 more
- (C7R)-GD2.CART cells
- +2 more
-
Houston, TexasTexas Children's Hospital
Feb 7, 2022
Relapsed/Refractory Multiple Myeloma(MM) Trial in Guangdong (CART therapy in Relapsed/Refractory multiple myeloma)
Terminated
- Relapsed/Refractory Multiple Myeloma(MM)
- CART therapy in Relapsed/Refractory multiple myeloma
-
Guangdong, Guangdong, ChinaSouthern Medical University Zhujiang Hospital
Sep 17, 2021
B-cell Lymphoma Trial in Hangzhou (PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells)
Active, not recruiting
- B-cell Lymphoma
- PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells
-
Hangzhou, Zhejiang, ChinaThe First Affiliated Hospital, Zhejiang University School of Med
Sep 28, 2022
Lymphoblastic Leukemia, Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Leukemia in Children Trial in Singapore (Phase
Recruiting
- Lymphoblastic Leukemia
- +4 more
- Phase I
- Phase II
-
Singapore, SingaporeKK Women's and Children's hospital
Jun 20, 2022
T-cell Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma Trial in Australia, United States (WU-CART-007)
Recruiting
- T-cell Acute Lymphoblastic Leukemia
- Lymphoblastic Lymphoma
- WU-CART-007
-
Duarte, California
- +7 more
Jun 22, 2022
CART Treatment, B Cell Lymphoma Trial in Tel-Aviv (Eltrombopag)
Recruiting
- CART Treatment
- B Cell Lymphoma
-
Tel-Aviv, IsraelTel-Aviv Sourasky Medicak center / BMT Unit
Apr 14, 2022
Acute Myeloid Leukemia Trial in Suzhou (anti-CLL1 CART)
Recruiting
- Acute Myeloid Leukemia
- anti-CLL1 CART
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
May 10, 2021
Large B-cell Lymphoma, B-cell Lymphoma Trial in Houston (Magrolimab, Rituximab, CAR T leukapheresis)
Not yet recruiting
- Large B-cell Lymphoma
- B-cell Lymphoma
- Magrolimab
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Jun 29, 2023
T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma Trial (CD7-CART01)
Not yet recruiting
- T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
- CD7-CART01
- (no location specified)
Sep 26, 2023
Diffuse Large B-cell Lymphoma Trial in Worldwide (MB-CART2019.1, R-GemOx or BR plus polatuzumab vedotin)
Recruiting
- Diffuse Large B-cell Lymphoma
- MB-CART2019.1
- R-GemOx or BR plus polatuzumab vedotin
-
Graz, Austria
- +55 more
Jan 5, 2023
Leukemia, Acute, Leukemia, Lymphoblastic Trial in Ann Arbor (Education information system, Activity monitor, Interview)
Enrolling by invitation
- Leukemia, Acute
- Leukemia, Lymphoblastic
- Education information system
- +4 more
-
Ann Arbor, MichiganUniversity of Michigan
Feb 8, 2022
Hairy Cell Leukemia, Hairy Cell Leukemia Variant Trial run by the NCI (CD22CART cell infusion)
Recruiting
- Hairy Cell Leukemia
- Hairy Cell Leukemia Variant
- CD22CART cell infusion
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 25, 2023
Refractory HIV Associated Kaposi Sarcoma Trial (Dostarlimab in Combination Antiretroviral Therapy)
Not yet recruiting
- Refractory HIV Associated Kaposi Sarcoma
- Dostarlimab in Combination Antiretroviral Therapy
- (no location specified)
Dec 2, 2022
Follicular Lymphoma, B-Cell Lymphoma, Mantle Cell Lymphoma Trial in New York (Tazemetostat Pill)
Not yet recruiting
- Follicular Lymphoma
- +3 more
- Tazemetostat Pill
-
New York, New YorkWeill Cornell Medicine/NewYork-Presbyterian Hospital
Jun 28, 2023
FDG-PET/CT Imaging as Early Predictor of DP
Completed
- Lymphoma
- There is no intervention
-
Philadelphia, PennsylvaniaAbramson Cancer Center of the University of Pennsylvania
Mar 7, 2022
Castrate-Resistant Prostate Cancer Trial in Hangzhou (PD1-PSMA-CART cells)
Recruiting
- Castrate-Resistant Prostate Cancer
- PD1-PSMA-CART cells
-
Hangzhou, Zhejiang, ChinaThe First Affiliated Hospital, Zhejiang University
Feb 26, 2022
B-cell Non Hodgkin Lymphoma Trial in Augsburg, Cologne, Hamburg (MB-CART2019.1 Dose level 1, MB-CART2019.1 Dose level 2)
Active, not recruiting
- B-cell Non Hodgkin Lymphoma
- MB-CART2019.1 Dose level 1
- MB-CART2019.1 Dose level 2
-
Augsburg, Bavaria, Germany
- +2 more
Jun 13, 2022
Multiple Myeloma Trial in Zhengzhou (PD1-BCMA-CART)
Not yet recruiting
- Multiple Myeloma
- PD1-BCMA-CART
-
Zhengzhou, Henan, ChinaFirst Affliated Hospital of Zhengzhou University
May 15, 2022
Therapy Related Leukemia Trial in Guangdong (Sequential Treatment With different CART)
Recruiting
- Therapy Related Leukemia
- Sequential Treatment With different CART
-
Guangdong, Guangdong, ChinaSouthern Medical University Zhujiang Hospital
Aug 9, 2021